Skip to main content
SpringerLink
Log in
Book cover

Gene Therapy for Cancer pp 399–411Cite as

Phase I Clinical Experience with Intravenous Administration of PV701, an Oncolytic Virus

  • Chapter

  • 1527 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

PV701 is a highly purified, replication-competent naturally attenuated strain of Newcastle disease virus, an avian paramyxovirus. PV701 directly lyses diverse human cancer cells in vitro (oncolytic) while being significantly less toxic toward normal human cells. In addition to its direct oncolytic properties, PV701 is capable of stimulating T-cell-mediated specific antitumor immunity and nonspecific activation of immune function, including interferon release and activation of tumoricidal macrophages. A high rate of complete tumor regression is observed in athymic mice implanted with human tumor cells following PV701 administered intravenously, or by intraperitonel or intratumoral routes. Objective responses have been observed in human phase I clinical trials of diverse tumor types. PV701 thus warrants further study as a novel therapeutic agent for cancer patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251–2266.

    Article  PubMed  CAS  Google Scholar 

  2. Lorence RM, Pecora AL, Major PP, et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 2003;5:618–624.

    PubMed  CAS  Google Scholar 

  3. Lorence RM, Roberts MS, Groene WS, Rabin H. Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In: Replication-Competent Viruses for Cancer Therapy, Hernaiz Driever P, Rabkin SD, eds., Monographs in Virology. Basel, Switzerland: Karger 2001;22: pp. 160–182.

    Chapter  Google Scholar 

  4. Hallden G, Thorne SH, Yang J, Kirn DH. Replication-selective oncolytic adenoviruses. Methods Mol Med 2004;90:71–90.

    PubMed  CAS  Google Scholar 

  5. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001;61:7464–7472.

    PubMed  CAS  Google Scholar 

  6. Kanevera A, Bauerachmitz GJ, Yamamoto M, et al. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther 2004; 11(6): 552–559.

    Article  Google Scholar 

  7. Markert JM, Medlock MD, Rapkin ST, et al. Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant gliomas: Results of a Phase I trial. Gene Ther 2000;7:867–874.

    Article  PubMed  CAS  Google Scholar 

  8. Yang WQ, Senger DL, Lun XQ, et al. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther 2004;11: 1579–1589.

    Article  PubMed  CAS  Google Scholar 

  9. Thorne SH, Kirn DH. Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus. Expert Opin Biol Ther 2004;4:1307–1321.

    Article  PubMed  CAS  Google Scholar 

  10. Sypula J, Wang F, Ma Y, et al. Myxoma virus tropism in human tumor cells. Gene Ther Mol Biol 2004;18:103–114.

    Google Scholar 

  11. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4:263–275.

    Article  PubMed  CAS  Google Scholar 

  12. Lichty BD, Stojdl DF, Taylor RA, et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004; 15:821–831.

    Article  PubMed  CAS  Google Scholar 

  13. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821–825.

    Article  PubMed  CAS  Google Scholar 

  14. Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003;77:8843–8856.

    Article  PubMed  CAS  Google Scholar 

  15. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004;103:1641–1646.

    Article  PubMed  CAS  Google Scholar 

  16. Ochiai H, Moore SA, Archer GE, et al. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res 2004; 10:4831–4838.

    Article  PubMed  CAS  Google Scholar 

  17. Shafren DR, Au GG, Nguyen T, et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus A21. Clin Cancer Res 2004; 10:53–60.

    Article  PubMed  CAS  Google Scholar 

  18. Raykov Z, Balboni G, Aprahamian M, Rommelaere J. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 2004; 109:742–749.

    Article  PubMed  CAS  Google Scholar 

  19. Mustar T, Rajtarova J, Sachet M, et al. Interferon resistance promotes oncolysis by influenza virus NSl-deletion. Int J Cancer 2004;110:15–21.

    Article  Google Scholar 

  20. Welch AR, McDaniel GP, Sudarshan C, et al. The broad spectrum oncolytic activity of Newcastle disease virus PV701 is a result of a functional defect in the antiviral interferon response in tumor cells. Eur J Cancer 2001;37(l): S69.

    Article  Google Scholar 

  21. Lorence RM, Roberts S, Groene WS, et al. Regression of human tumor xenografts following intravenous treatment using PV701, a naturally attenuated oncolytic strain of Newcastle disease virus. Proc Am Assoc Cancer Res 2001;42:454 (abst # 2442).

    Google Scholar 

  22. Roberts MS, Buasen PT, Incao BA, et al. PV701, a naturally attenuated strain of Newcastle disease virus, has a broad spectrum of oncolytic activity against human tumor xenografts. Proc Amer Assoc Cancer Res 2001;42:454 (abst # 2441).

    Google Scholar 

  23. Savage PD, Muss HB. Renal Cell Cancer. In: Biologic Therapy of Cancer. Devita VT, Hellman S, Rosenberg SA, eds., Philadelphia, PA: JB Lippincott 1995;pp.373–387.

    Google Scholar 

  24. Laurie SA, Atkins HL, Bell JC, et al. Novel 2-step desensitization dosing regimen of intravenous PV701, an oncolytic virus, results in improved tolerability: A phase I study of patients with advanced solid tumours. Eur J Cancer 2002;38(7): Abs 516.

    Google Scholar 

  25. Hotte SJ, Major PP, Hirte HW, et al. Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. J Clin Oncol 2004; 22:204 (Abstr #3037).

    Google Scholar 

  26. Zeisberger E, Roth J. Tolerance to pyrogens. Ann N Y Acad Sci 1998;856:116–131.

    Article  PubMed  CAS  Google Scholar 

  27. Bergsland EK, Venook AR Shedding old paradigms: Developing viruses to treat cancer. J Clin Oncol 2002;20:2220–2222.

    PubMed  Google Scholar 

  28. Sze DY, Freman SM, Slonin SM, et al. Dr. Gary J. Becker Young Investigator Award: Intraarterial adenovirus for metastatic gastrointestinal cancer: Activity, radiographie response, and survival. J Vasc Interv Radiol 2003; 14:279–290.

    PubMed  Google Scholar 

  29. Newcastle disease virus vaccine. United States Code of Federal Regulations. 1999; Title 9, Part 1213, Section 329.

    Google Scholar 

  30. Thorton DH. Quality control of vaccines. In: Newcastle Disease. Alexander DJ, ed., Boston, MA: Kluwer Academic Publishers 1988;pp.347–365.

    Google Scholar 

  31. Miller LT, Yates VJ. Reactions of human sera to avian adenoviruses and Newcastle disease virus. Avian Dis 1971;15:781–788

    Article  PubMed  CAS  Google Scholar 

  32. Charan S, Mahajan VM, Agarwal L. Newcastle disease virus antibodies in human sera. Indian J Med Res 1981;73:303–307.

    PubMed  CAS  Google Scholar 

  33. Nemunaitis J, Cunningham C, Tong AW, et al. Pilot study of intravenous infusion of a replicationselective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003;10:341–352.

    Article  PubMed  CAS  Google Scholar 

  34. Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:1498–1504.

    Article  PubMed  CAS  Google Scholar 

  35. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (d11520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther 2001;8:1618–1626.

    Article  PubMed  CAS  Google Scholar 

  36. Reid T, Galanis E, Abbruzzese J, et al. Hepatic artery infusion of a replication-selective oncolytic adenovirus (d11520): Phase II Viral, immunologic, and clinical endpoints. Cancer Res 2002;62: 6070–6079.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Cancer Center, Hackensack University Medical Center, Hackensack, NJ

    Andrew L. Pecora MD

  2. Wellstat Biologics Corporation, Gaithersburg, MD

    Robert M. Lorence MD, PhD

Authors
  1. Andrew L. Pecora MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert M. Lorence MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Texas M. D. Anderson Cancer Center, Houston, TX

    Kelly K. Hunt MD  & Stephen G. Swisher MD  & 

  2. Inselspital Bern, University of Bern, Bern, Switzerland

    Stephan A. Vorburger MD, MCR

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Pecora, A.L., Lorence, R.M. (2007). Phase I Clinical Experience with Intravenous Administration of PV701, an Oncolytic Virus. In: Hunt, K.K., Vorburger, S.A., Swisher, S.G. (eds) Gene Therapy for Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-222-9_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-222-9_22

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-472-2

  • Online ISBN: 978-1-59745-222-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation